Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.21 USD
Change Today +0.0077 / 3.84%
Volume 390.2K
ELTP On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

elite pharmaceuticals inc (ELTP) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/13/14 - $0.40
52 Week Low
12/1/14 - $0.17
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

elite pharmaceuticals inc (ELTP) Related Businessweek News

No Related Businessweek News Found

elite pharmaceuticals inc (ELTP) Details

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and licensing of proprietary controlled-release drug delivery systems and products. It develops orally administered controlled-release products that comprise drugs that cover various therapeutic areas, including pain, allergy, and infection. The company owns, licenses, or contract manufactures Phentermine HCl tablets, Lodrane D Immediate Release capsules, Methadone HCl tablets, Hydromorphone HCl tablets, Phendimetrazine tartrate tablets, Naltrexone HCl tablets, Isradipine capsules, and Hydroxyzine tablets. It is also developing abuse resistant opioid products. In addition, the company engages in the contract research and development activities on behalf of other pharmaceutical companies. Elite Pharmaceuticals, Inc. was founded in 1984 and is headquartered in Northvale, New Jersey.

36 Employees
Last Reported Date: 06/15/15
Founded in 1984

elite pharmaceuticals inc (ELTP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $700.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $216.6K
Executive Vice President of Operations
Total Annual Compensation: $300.2K
Head of Development
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

elite pharmaceuticals inc (ELTP) Key Developments

Elite Pharmaceuticals Reports Consolidated Revenue Results for the Year Ended March 31, 2015

Elite Pharmaceuticals reported consolidated revenue results for the year ended March 31, 2015. For the period, the company’s revenues were USD 5.015 million against USD 4.6 million a year ago. The company announced the increase in fiscal 2015 revenues is due to the continued growth and expansion of its generic product lines, with the launch of Isradipine 2.5 mg and 5.0 mg capsules during Fiscal 2015.

Elite Pharmaceuticals, Inc. to Report Fiscal Year 2015 Results on Jun 15, 2015

Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2015 results at 9:30 PM, GMT Standard Time on Jun 15, 2015

Elite Pharmaceuticals, Inc. and Epic Pharma LLC Enter into Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

Elite Pharmaceuticals, Inc. announced that it has entered into a sales and distribution licensing agreement with Epic Pharma LLC for ELI-200, an abuse-deterrent opioid utilizing Elite's proprietary pharmacological abuse-deterrent technology. Epic will be responsible for sales and marketing of ELI-200, and Elite will be responsible for the manufacture of the product. Epic will pay Elite non-refundable milestone payments totaling $15 million and a royalty based on net product sales. The term of the License is five years and the License is renewable upon mutual agreement at the end of the initial term.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELTP:US $0.21 USD +0.0077

ELTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $63.07 USD -1.70
Durect Corp $2.26 USD -0.08
Egalet Corp $12.42 USD +0.32
Nektar Therapeutics $11.89 USD -0.23
Zogenix Inc $12.80 USD -1.16
View Industry Companies

Industry Analysis


Industry Average

Valuation ELTP Industry Range
Price/Earnings 5.4x
Price/Sales 25.7x
Price/Book NM Not Meaningful
Price/Cash Flow 4.4x
TEV/Sales 16.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELITE PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at